APUS logo

APIMEDS PHARMACEUTICALS US I

APUSNYSE AMERICAN
๐Ÿ† #4252 by market capUS Equity
$4.63โ–ฒ $0.43 (+9.20%)
๐ŸŒ… Pre-market$4.63โ–ฒ 0.00%Regular close ยท extended-hours price shown
1hโ€”
24hโ–ฒ 9.2%
7dโ–ผ 3.5%
14dโ–ผ 19.8%
30dโ–ผ 36.5%
1yโ–ผ 70.7%
๐ŸฆMarket Cap
$7M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
+0.0%
Slowing
๐Ÿ“ŠGross Margin
0.0%
Thin
๐Ÿ’ตFCF Margin
0.0%
Thin
โš–๏ธP/S Ratio
0.0x
Cheap
Otter Score
54
Weak

Trading Snapshot

Day Range
$4.60 โ€“ $4.69
52-Week Range
$4.15 โ€“ $59.70
Volume
$4.69B
Avg Volume
$5.95B
Shares Outstanding
1.5M
Next Earnings
Sep 23, 2026

Fundamentals Snapshot

Annual Revenue
$602,346
Last Q Revenue
$143,290
P/E Ratio
-0.1
P/S Ratio
0.0x
EPS (TTM)
$-26.21
Dividend Yield
0.00%

Why Investors Own APUS

  • โœ“High-growth profile โ€” revenue up +50.6% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 37% gross margin and 5% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$602,346โ–ฒ +57.1% YoY
Gross Margin (TTM)
37.3%โ–ฒ +1.1% YoY
Operating Income (TTM)
$200,581โ–ฒ +57.1% YoY
Free Cash Flow (TTM)
$29,515โ–ฒ +57.1% YoY

About APIMEDS PHARMACEUTICALS US I

Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox โ€“ from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
54/100

Analyst Price Target

โ“˜
Average Target
$4.76
โ–ฒ +2.8% Upside
High Target$5.97
Low Target$4.18
Based on 10 analysts

Latest News & Updates